TargetMol

SPD304

Product Code:
 
TAR-T12985L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T12985L-5mg5mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12985L-50mg50mg£815.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T12985L-100mg100mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SPD304 is a selective TNF-α inhibitor and blocks the interaction of TNF and its receptor. SPD304 has an IC50 of 22 ?M for inhibiting in vitro TNF receptor 1 binding to TNF-α.
CAS:
869998-49-2
Formula:
C32H32F3N3O2
Molecular Weight:
547.622
Pathway:
Apoptosis
Purity:
0.98
SMILES:
CN(CCN(C)Cc1coc2cc(C)c(C)cc2c1=O)Cc1cn(-c2cccc(c2)C(F)(F)F)c2ccccc12
Target:
TNF

References

1. Molly M. He, et al. Small-Molecule Inhibition of TNF-?. Science 11 Nov 2005. 2. Alexiou P, et al. Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects. Arch Pharm (Weinheim). 2014 Nov;347(11):798-805. 3. Mouhsine H, et al. Identification of an in vivo orally active dual-binding protein-protein interaction inhibitor targeting TNF? through combined in silico/in vitro/in vivo screening. Sci Rep. 2017 Jun 13;7(1):3424. 4. Gallic acid induces necroptosis via TNF-? signaling pathway in activated hepatic stellate cells. Chang YJ, et al. PLoS One. 2015 Mar 27;10(3):e0120713.